ApoRepair is a French biotech company emerging from the National Center for Scientific Research (CNRS) that aims to improve the management of patients in the acute phase of myocardial infarction (MI). Reperfusion of the heart, essential to save the patient's life, generates adverse effects that diminish the expected benefit. Our therapeutic peptide protects the myocardium and improves the effects of reperfusion. This patented technology is based on a collaborative team effort spanning more than 15 years.

ApoRepair

Org chart

Teams

Offices